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Setting: Masih Daneshvari Hospital, Tehran, Iran, 2000—2002.
Objective: To evaluate the effectiveness of multiple drug-resistant tuberculosis
(MDR-TB) treatment for the first time in Iran.
Design: All cases of MDR-TB with complete follow-up data were recruited and results
of their treatments were evaluated.
Results: MDR-TB treatment was initiated with 5.23 drugs, on average. Isoniazid,
amikacin, and ofloxacin were present in the drug regimen of all patients. Average
duration of the treatment was 18.5 months (range, 7—36). Over 76% of the patients
responded to the treatment (negative smear and culture). Cure and probable cure
were documented in seven (41.2%) and four (23.5%) of the patients, respectively. No
failure in the treatment occurred when cycloserine was present in the treatment
regimen.
Conclusion: A majority of the MDR-TB patients in Iran can be cured with the use of
appropriate treatment regimens. An even greater success could be achieved by
providing more second-line drugs.
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Over the past two decades there has been a world-
wide increase in the number of multiple drug-
resistant tuberculosis (MDR-TB) cases.1 Once a
strain of Mycobacterium tuberculosis develops
combined resistance to isoniazid and rifampin, it
is defined as MDR-TB.2 MDR-TB cases are classified
into two categories: those who have primary resis-
tance and those who have acquired resistance,
consisting of the majority of cases. Insufficient
previous treatment is a strong prognostic factor
in the development of MDR-TB. Many of the MDR-
TB patients had been taking anti-TB drugs for a
long time, and often irregularly, which resulted in
treatment failure.3 It has also been shown that
people who have primary resistance and who fre-
quently fail treatment may become gradually more
resistant and difficult to cure.4
Diagnosis, treatment and follow-up of MDR-TB
cases are complex and costly. In order to diagnose
MDR-TB cases, there needs to be proper facilities for
mycobacterial culture and drug-susceptibility test-
ing.5 MDR-TB treatment, which is usually based on
using three or more effective drugs, is labor inten-
sive and dependent on close cooperation between
both patient and physician.6 Therefore, the admin-
istration of MDR-TB treatment is suggested only in
centers where skilled physicians, an isolation facil-
ity and a mycobacteriology reference center exist.5
Many studies have investigated MDR-TB treat-
ment worldwide.7—26 Here, the first study on MDR-
TB treatment in Iran is reported. It was carried out
at Masih Daneshvari Hospital in Tehran between
2000—2002.Materials and methods
Setting
Masih Daneshvari Hospital, which acts as the refer-
ence unit for the National Tuberculosis Program
(NTP), is the only center for the treatment of
MDR-TB patients in Iran. This hospital has various
diagnostic and therapeutic facilities such as the
mycobacteriology reference laboratory, broncho-
scopy, pathology, radiology, and thoracic surgery
departments.
Diagnosis
A sputum sample from all patients was cultured in
Lowenstein-Jensen medium. Drug-susceptibility
testing was performed by the standardized method
of proportion.27—29 Susceptibility was determinedon the basis of the following drugs and concentra-
tions: isoniazid 0.2 mg/ml, rifampin 40 mg/ml,
ethambutol 2 mg/ml and streptomycin 4 mg/ml.
Drug-susceptibility testing was not carried out for
pyrazinamide. Resistance was defined as the growth
of more than 1% of colonies on drug-containing
medium as well as on drug-free medium.
Treatment
According to the NTP protocol, new cases were
treated with four first line drugs: isoniazid, rifam-
pin, pyrazinamide, and ethambutol. Where a posi-
tive sputum smear was detected after five months,
treatment was considered to have failed and cases
were hospitalized with suspected MDR-TB. Che-
motherapy for each patient was administered based
on his/her drug treatment history. Drug regimens
mainly comprised a combination of first and second
line drugs. An aminoglycoside (mainly amikacin,
15 mg/kg) was included in the treatment program
for all patients unless it was contraindicated. All
patients received ofloxacin 600—800 mg/day and
cycloserine, if prescribed was given at 500 mg/
day. Due to the lack of ethionamide and other
second line drugs in Iran, isoniazid at 15 mg/kg
was added to all MDR-TB regimens.30 The treatment
period continued for at least 18 months after
achieving the first negative sputum culture, or at
least 24 months when no first line drug was used.
The patients were hospitalized until their sputum
became negative. The Iranian Ministry of Health
along with some charities provided the treatment
at no cost to the patients. After discharge, follow-up
evaluations included a sputum smear and culture
every month and chest X-ray every three months.
Recruitment of participants
Between 2000—2002, 39 patients were referred to
the center. They had a history of at least one pre-
vious period of TB treatment under the center’s
direct observation, two positive sputum smear
tests, and a positive sputum culture. Their antibio-
gram showed resistance to at least isoniazid and
rifampin, and their chest X-ray and clinical symp-
toms were compatible with pulmonary TB. Other
inclusion criteria were documentation of at least six
months of follow-up after the initiation of the treat-
ment. Out of 39 patients, 17 were eligible to enter
the study. The 22 patients who were not eligible
included seven without positive culture in the lab
due to technical problems, and 15 who did not have
adequate follow-up data.
Various information about age, sex, marital
status, nationality, duration of the presence of
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Table 1 Definition of outcome based on the recommendations of the World Health Organization.
Outcome Definition
Response to treatment Conversion from positive to negative smears and cultures during treatment
Successful outcome
Probable cure Negative smears and cultures throughout treatment for at least six months
Cure Negative smears and cultures throughout treatment for at least 18 months
(or 24 months, in the absence of first line drugs)
Poor outcome
Treatment failure Persistence of positive smears or cultures despite treatment for at least
18 or 24 months
Incomplete treatment Failure to complete treatment because of adverse effects or for other reasons
Death Death from tuberculosis or complications of treatment
Relapse Recurrence of positive smear or culture after achievement of a curesymptoms before MDR-TB diagnosis, duration of
anti-TB drug regimen and resistance to different
drugs were collected from patients’ medical
records. As illustrated in Table 1, the outcome of
treatment was defined based on the recommenda-
tions of the World Health Organization (cure, prob-
able cure, failure and relapse).31 Information about
the time of change in smear and culture to negative
after the treatment, duration of hospitalization and
duration of treatment with aminoglycosides was
elicited from the patients’ medical records. Radi-
ological presentations were classified as bilateral
pulmonary involvement with cavity, bilateral pul-
monary involvement without cavity, cavitary
lesions, and non-cavitary non-bilateral pulmonary
involvement.
Findings were analyzed using SAS 8e. Nominal
variables were analyzed by the Chi-square test
(Fisher’s exact test whenever necessary). Student’s
t-test (for normally distributed variables) and the
Mann-Whitney U-test (for non-normally distributed
variables) were used for continuous variables. A
p-value of less than 0.05 was considered statistically
significant.
The study was approved by the Institutional
Review Board at the National Research Institute of
Tuberculosis and Lung Diseases in Tehran.Results
Seventeen patients took part in the study. The mean
age of the patients was 34.1 (17—70) years. Twelve
(71%) patients were male and five patients (29%)
were female. Thirteen (77%) patients were from
Afghanistan and the remainder were Iranian.
Some of the main characteristics of the patients
and their response to the treatment are summarized
in Table 2. Three patients (17.6%) had concomitant
diseases including one case of alcoholism, one caseof hypertension, and one case of cor-pulmonale. All
patients had a history of TB and had had prior
treatment. On average, patients had taken 4.9
anti-TB drugs for two time periods before the initia-
tion of MDR-TB treatment. The mean duration of the
respiratory symptoms before the initiation of MDR-
TB treatment protocol was 27.9 (12—96) months.
Patients were, on average, resistant to 3.6 drugs.
All of them were resistant to isoniazid and rifampin.
Over three quarters (76.5—88.2%) were resistant to
ethambutol and streptomycin, respectively.
MDR-TB treatment was initiated with 5.23 drugs,
on average. Isoniazid, amikacin, and ofloxacin were
present in the drug regimen of 100% of the patients.
The proportion of patients receiving pyrazinamide,
ethambutol, and cycloserine was 94.1%, 88.2%, and
41.2%, respectively. Duration of the treatment was,
on average, 18.5 months (range, 7—36). Duration of
treatment with aminoglycosides was 6.8 months
(range, 2—17). Over 76% of the patients responded
to the treatment (negative smear and culture). Cure
and probable cure were documented in seven
(41.2%) and four (23.5%) of the MDR-TB patients,
respectively. Treatment in four cases (23.5%) failed.
One patient, who showed a response to the treat-
ment, was classified into neither the cure nor prob-
able cure categories. Relapse and death each
occurred in one case (5.9%). One patient underwent
surgery.
Among the patients who did not receive cyclo-
serine, four cases (40%), four cases (40%), and
two cases (20%) were classified into treatment
failure, cure, and probable cure categories,
respectively. Among those who received cyclo-
serine, two cases (28.6%) responded to the treat-
ment, two cases (28.6%) showed probable cure,
and three cases (42.9%) were cured completely.
Treatment failed in no cases.
There was no statistically significant difference
between the group of patients with successful
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Table 2 Characteristics of patients and their response to the treatment regimens.
Characteristics/response to the treatment Values







Marital status, no. (%)
Single 8 (47.1)
Married 9 (52.9)
Mean duration of the symptoms before the initiation
of MDR-TB treatment in months (range)
27.9 (12—96)
Mean duration of the MDR-TB treatment in months (range) 18.5 (7—36)
Mean time for smear to become negative in months (range) 4.2 (1—12)
Mean time for culture to become negative in months (range) 4.7 (2—14)
Treatment response, no. (%)
Probable cure 4 (23.5)
Cure 7 (41.2)
Treatment failure 4 (23.5)
Death 1 (5.9)
Relapse 1 (5.9)outcomes and the group with unsuccessful out-
comes, with regard to age, sex, number of drugs
used previously, number of drugs to which patients
were resistant, and the presence of cycloserine in
the treatment protocol. However, the duration of
treatment for patients with unsuccessful treatment
(28 months) was significantly higher than those with
successful treatment (16.6 months) ( p = 0.04).
It should be noted that all of the patients in this
study were tested for HIV infection after consent.
No patients were HIV positive.Discussion
This study shows a notable success in the treatment
of multiple drug-resistant tuberculosis in Iran. Bac-
teriologic cure occurred in 76.5% of the patients.
Cure and probable cure occurred in 41.2% and 23.5%
of the patients respectively, giving a 64.7% rate of
success in the treatment. Although these numbers
are lower than in some similar studies found in the
region and in Asia,17,22 they do show that even with a
shortage of second-line drugs, MDR-TB is curable.
The mean age of the patients in this study was 34
years which is generally less than that reported in
other studies.10,11,16 The majority of the cases were
male, as has been documented in other reports.9,10
In contrast to some previous studies,15,22 the major-
ity of the patients in the present study were mar-ried. In this study, only three patients (17.6%) had
current or previous concomitant diseases, while in
some studies more than half the patients had a
concomitant disease.15,22 Furthermore, as pre-
viously mentioned, none of the patients in this study
were HIV positive; however, a significant number of
the patients in some of the other studies were HIV
positive.8,18,20 On average, the patients had
received 4.8 drugs and were resistant to 3.6 drugs
before the initiation of the treatment. These find-
ings are consistent with those of other studies.10,17
All the patients were resistant to isoniazid and
rifampin. Eighty-eight percent and 76.5% were resis-
tant to streptomycin and ethambutol, respectively.
Of great concern is that in some parts of the world
(as Abate has reported from Ethiopia)7 MDR-TB cases
are completely sensitive to ethambutol, which is
due to not using it as a first-line drug. Similarly, in
other parts of the world, resistance to ethambutol is
low.9,32
The patients received on average 5.23 drugs,
which is similar to the number of drugs used in other
studies.11,20,22 There was one case of relapse and
one death (5.9%) in this study which is similar to
countries where MDR-TB treatment has been suc-
cessful.17 The average time of the change for the
smear and culture from positive to negative was 4.2
and 4.7 months, respectively, which is longer com-
pared to other reports. In the study by Tahaoglu
et al.22 from Turkey, the average time of change for
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study by Hadiatro et al.13 from Indonesia, the spu-
tum smear conversion rate was 50% over three
months. The lack of effective second line drugs
(e.g. prothionamide) in the authors’ treatment pro-
tocol is the reason for the longer average time in this
study. Of the MDR-TB patients in this study, only one
case underwent surgery, which is lower compared to
other studies.11 Therefore, further work in this area
is needed. Consistent with the results of other
reports regarding the radiology presentations, the
majority of the patients had bilateral cavitary
lesions.7
Patients with unsuccessful treatment had a
longer stay in hospital (and a longer duration of
treatment) and this is consistent with the decision
to finish the hospitalization period after achieving
negative sputum.
The main limitation of this study was its small
sample size. This is because this was a preliminary
report from the first Iranian MDR-TB treatment
project. Had the study been larger, the potential
differences between the patients with successful
outcomes and those with unsuccessful outcomes
might have been more apparent. For instance,
although cycloserine did have a noticeable effect
in making the sputum negative (there was no treat-
ment failure when cycloserine was present), this
difference did not gain statistical significance.Conclusion
Tuberculosis is considered one of the main health
issues in Iran. One of the main reasons which has
contributed to this problem is the fact that Iran
borders Afghanistan. According to the World Health
Organization, the reported and estimated number
of TB cases in Iran is 17 and 52 per 100,000 persons,
respectively. For Afghanistan there are 44 and 314
reported and estimated cases per 100,000 persons,
respectively.33 During the past two decades, immi-
grants from Afghanistan have flooded into Iran.34
Based on the high prevalence of TB in Afghanistan
and also due to the nature of this disease, it is
believed that there are considerable numbers of
cases of active, latent, and multiple drug-resistant
TB infection among Afghan refugees, and legal or
illegal immigrants in Iran. In this study, Afghan
immigrants made up the majority of the patients.
MDR-TB requires specific drugs and a longer dura-
tion of hospitalization compared to TB. By using
current chemotherapy protocols, acceptable success
in MDR-TB treatment was achieved among the
patients in this study. It is believed that even greater
success could be achieved by providing more secondline drugs. Furthermore, by improving the surgery
systemand increasing thenumberofMDR-TBpatients
eligible for surgery, it is hoped that a greater number
of these patients will be cured in Iran.References
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